Shares of Celldex Therapeutics, Inc. (CLDX) are rising more than 20 percent or $2.59 in Monday's morning trade at $15.39, after touching a new 52-week high of $15.65 earlier despite no specific news that could influence the stock.
U.S. stocks are rising on Monday, extending gains from the previous session, as investors shrugged off concerns about a surge in coronavirus cases and uncertainty about the U.S. presidential election.
Celldex is a biopharmaceutical company that focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics.
Celldex Therapeutics has traded in a range of $1.50 to $15.65 in the past 52 weeks.
For comments and feedback: editorial@rttnews.com